Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 8/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 8/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 8/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485247 | 0.90 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAPKMMEN1 | |
| SCHEMBL31016431 | 0.81 | S1PR1 (0.53) | ALDH1A1KDM4ELMNAPKMMAPT | |
| SCHEMBL3485924 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAPKMMEN1 | |
| SCHEMBL28626119 | 0.79 | EED (0.63) | ALDH1A1KDM4EMEN1NPC1GAA | |
| SCHEMBL30101923 | 0.79 | EED (0.63) | ALDH1A1KDM4EMEN1NPC1GAA | |
| Hydrochloric Acid SCHEMBL11445323 | 0.79 | ALDH1A1 (0.53) | ALDH1A1KDM4ELMNAPKMMEN1 | |
| SCHEMBL28338201 | 0.78 | ALDH1A1 (0.78) | ALDH1A1KDM4ELMNAPKMMEN1 | |
| SCHEMBL10539432 | 0.78 | ALDH1A1 (0.79) | ALDH1A1KDM4EMAPTNPSR1BACE1 | |
| SCHEMBL3484761 | 0.78 | MAPT (0.64) | ALDH1A1LMNAPKMMEN1MAPT | |
| SCHEMBL28620033 | 0.77 | MAPT (0.46) | ALDH1A1KDM4EPKMMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B9 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2019-05-22 | — | — | EP | disclosed |
| EP-2666481-B1 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA MASATOSHI (JP) | 2018-11-14 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-1712242-B1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA MASATOSHI (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8816089-B2 | Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity | Hagiwara, Masatoshi (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-101837125-B | Method of regulating phosphorylation of PTH protein and antiviral agents comprising SR protein activity regulator as the active ingredient | HAGIWARA MASATOSHI | 2014-02-26 | — | — | CN | disclosed |
| EP-2666481-A2 | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient | HAGIWARA, Masatoshi (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-7569536-B2 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | Hagiwara, Masatoshi (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | HAGIWARA, MASATOSHI (JP) | 2007-06-14 | — | — | US | disclosed |
| CN-1921885-A | Method for controlling phosphorylation of SR protein and antiviral agent comprising SR protein activity controller as active ingredient | HAGIWARA MASATOSHI (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1712242-A1 | METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT | HAGIWARA, Masatoshi (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | ALDH1A1 399/4885KDM4E 4506/4885LMNA 1603/4885 |
| US-20070135367-A1 | Broad spectrum antiviral including against SARS (severe acute respiratory syndrome), DNA viruses and herpes viruses; Ser-Arg (SR), SR proteins are RNA-binding proteins; compounds are SRPK inhibitors such as 1-piperidino-2-(pyridin-4-ylcarbonylamino)-4-trifluoromethylbenzene | SRPK1, SARS1, SRPK3 | ALDH1A1 4791/4885KDM4E 529/4885LMNA 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.